These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23129333)

  • 41. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.
    Bachmann RF; Schloesser RJ; Gould TD; Manji HK
    Mol Neurobiol; 2005 Oct; 32(2):173-202. PubMed ID: 16215281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder.
    Soeiro-de-Souza MG; Dias VV; Figueira ML; Forlenza OV; Gattaz WF; Zarate CA; Machado-Vieira R
    Acta Psychiatr Scand; 2012 Nov; 126(5):332-41. PubMed ID: 22676371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving outcomes in patients with bipolar depression: a comprehensive review.
    Nierenberg AA; McIntyre RS; Sachs GS
    J Clin Psychiatry; 2015 Mar; 76(3):e10. PubMed ID: 25830453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment.
    de Bartolomeis A; Buonaguro EF; Iasevoli F; Tomasetti C
    J Psychopharmacol; 2014 Jun; 28(6):505-26. PubMed ID: 24554693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lithium as a Neuroprotective Agent for Bipolar Disorder: An Overview.
    Ochoa ELM
    Cell Mol Neurobiol; 2022 Jan; 42(1):85-97. PubMed ID: 34357564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drugs under early investigation for the treatment of bipolar disorder.
    Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
    Expert Opin Investig Drugs; 2015 Apr; 24(4):477-90. PubMed ID: 25704484
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical research on antipsychotics in bipolar disorder.
    Chou JC; Solhkhah R; Serper M
    J Psychiatr Pract; 2000 Nov; 6(6):310-21. PubMed ID: 15990492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential pharmacology of atypical antipsychotics: clinical implications.
    Masand PS
    Am J Health Syst Pharm; 2007 Jan; 64(2 Suppl 1):S3-8; quiz S24-5. PubMed ID: 17215475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder.
    Shaltiel G; Chen G; Manji HK
    Curr Opin Pharmacol; 2007 Feb; 7(1):22-6. PubMed ID: 17055337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should the term 'antipsychotic' be changed to 'multidimensional stabiliser' in bipolar disorder? Towards a new denomination for 'atypical antipsychotics'.
    Altamura AC; Dragogna F
    Aust N Z J Psychiatry; 2013 Aug; 47(8):707-9. PubMed ID: 23728532
    [No Abstract]   [Full Text] [Related]  

  • 51. Translating knowledge of genetics and pharmacology into improving everyday practice.
    Yatham LN
    Bipolar Disord; 2005; 7 Suppl 4():13-20. PubMed ID: 15948763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maintenance therapy for bipolar disorder.
    Thase ME
    J Clin Psychiatry; 2008 Nov; 69(11):e32. PubMed ID: 19200424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models.
    He J; Kong J; Tan QR; Li XM
    Cell Adh Migr; 2009; 3(1):129-37. PubMed ID: 19372744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atypical antipsychotics as enhancement therapy in rapid cycling mood states: a case study.
    Novac A
    Ann Clin Psychiatry; 1998 Sep; 10(3):107-11. PubMed ID: 9781473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Physiopathology of bipolar disorders: what have changed in the last 10 years?].
    Kapczinski F; Frey BN; Zannatto V
    Braz J Psychiatry; 2004 Oct; 26 Suppl 3():17-21. PubMed ID: 15597134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health.
    Beaulieu JM
    J Psychiatry Neurosci; 2012 Jan; 37(1):7-16. PubMed ID: 21711983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prioritization of research addressing antipsychotics for adolescents and young adults with bipolar disorder.
    Crowley MJ; McCrory DC; Chatterjee R; Gierisch JM; Myers ER; Schmit KM; Coeytaux RR; Correll CU; Kendrick AS; Sanders GD
    Ann Intern Med; 2014 Apr; 160(7):492-8. PubMed ID: 24567115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Schizophrenia and bipolar affective disorder: perspectives for the development of therapeutics.
    Sundram S; Joyce PR; Kennedy MA
    Curr Mol Med; 2003 Aug; 3(5):393-407. PubMed ID: 12942993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EEG does not predict response of manic patients to atypical antipsychotics.
    Reeves RR; Burke RS; Struve FA
    Clin EEG Neurosci; 2011 Apr; 42(2):VII. PubMed ID: 21675593
    [No Abstract]   [Full Text] [Related]  

  • 60. Signaling: cellular insights into the pathophysiology of bipolar disorder.
    Manji HK; Lenox RH
    Biol Psychiatry; 2000 Sep; 48(6):518-30. PubMed ID: 11018224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.